HBsAg Seroclearance in Chronic Hepatitis B

• DOI: 10.1097/mcg.0b013e3181dd558c
• Publication Date: 2010-06-09T10:59:48Z
• Authors: Ji Hoon Kim; Young Sun Lee; Hyun Jung Lee; Eileen Yoon; Young Kul Jung; Eun Suck Jong; Beom Jae Lee; Yeon Seok Seo; Hyung Joon Yim; Jong Eun Yeon; Jong-Jae Park; Jae Seon Kim; Young-Tae Bak; Kwan Soo Byun
• Keywords: Univariate analysis; Hepatitis B

The long-term clinical course, including the development of hepatocellular carcinoma (HCC) after hepatic B surface antigen (HBsAg) seroclearance is not established. We discovered that incidence HCC and risk factors for in chronic hepatitis (CHB) patients HBsAg seroclearance.During 28 years, 96 CHB with were retrospectively reviewed. These continued to undergo surveillance. median follow-up time from initial visit was 166.5 months (range, 7 321 mo).The mean age at 39.2 ± 10.6 years 46.4 9.9 respectively. significantly lower (P=0.03) spontaneous than treatment-associated seroclearance. During a 56 238 mo) seroclearance, 6 (6.5%) developed HCC. developing 55.8 10.3 years. On univariate analysis, evidence liver cirrhosis more 45 significant development. In multivariate only factor development.HCC can develop known cirrhosis. Patients who achieved older (>45) may have undiagnosed hence remain surveillance should be carried out both those patient populations.